Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors

(2012) Yu Chen Barrett et al.   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism

(2010) Bengt I. Eriksson et al.   Annual Review of Medicine

Beyond Hemoglobin A1c—Need for Additional Markers of Risk for Diabetic Microvascular Complications

(2010) Irl B. Hirsch   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Serum Transaminase Levels Should Be Measured Immediately Prior to Dosing in Early Phase I Clinical Trials

(2010) David Groen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays

(2010) A. HILLARP et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

(2010) Michael Rud Lassen et al.   LANCET

Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement

(2010) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

(2010) Zhaoqing Wang et al.   THROMBOSIS AND HAEMOSTASIS

Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development

(2010) Mike Ufer   THROMBOSIS AND HAEMOSTASIS

Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits

(2009) P. C. WONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

New Antithrombotic Drugs

(2008) Jeffrey I. Weitz et al.   CHEST

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

(2008) Bengt I Eriksson et al.   CLINICAL PHARMACOKINETICS

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION

Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits

(2008) P. C. WONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Apixaban, an oral, direct and highly selective factor Xa inhibitor:in vitro, antithrombotic and antihemostatic studies

(2008) P. C. WONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

(2008) et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Muscular exercise can cause highly pathological liver function tests in healthy men

(2007) Jonas Pettersson et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY